Cancer
Amgen combination cuts death risk in small cell lung cancer trial
In a late-stage trial, adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% versus Imfinzi alone.
Amgen said its Imdelltra combined with AstraZeneca's Imfinzi cut the risk of death by 58% compared with Imfinzi alone in a late-stage trial of patients with extensive-stage small cell lung cancer. CNBC reported that the full results were released Saturday. The findings were presented at the European Society for Medical Oncology Congress, according to CNBC.
The trial tested the combination as maintenance therapy after patients received initial treatment with Imfinzi and chemotherapy and their cancer had not progressed. Median overall survival was 21.1 months with the combination and 12.7 months with Imfinzi alone, the trial found. Amgen said nearly 80% of patients who started both drugs were alive at one year, compared with 53% receiving Imfinzi alone.
The study did not compare the combination with other first-line treatment approaches. Imdelltra is currently approved for patients whose small cell lung cancer has progressed while on, or after, platinum-based chemotherapy, CNBC reported.
